Float Short %

6.64

Margin Of Safety %

Put/Call OI Ratio

0.42

EPS Next Q Diff

-0.02

EPS Last/This Y

0.59

EPS This/Next Y

-0.09

Price

16.73

Target Price

Analyst Recom

1.25

Performance Q

16.59

Relative Volume

0.91

Beta

2.18

Ticker: ADPT

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	ADPT	14.86	0.30	0.47	2913
2025-12-10	ADPT	15.75	0.30	1.78	2917
2025-12-11	ADPT	15.43	0.33	0.13	2987
2025-12-12	ADPT	15.45	0.33	0.00	2977
2025-12-15	ADPT	15.69	0.33	0.00	2975
2025-12-16	ADPT	15.91	0.33	0.00	2981
2025-12-17	ADPT	16.13	0.33	0.02	2990
2025-12-18	ADPT	16.52	0.32	0.48	3007
2025-12-19	ADPT	16.99	0.31	0.03	3115
2025-12-22	ADPT	17.42	0.31	0.30	2432
2025-12-23	ADPT	16.76	0.32	2.80	2554
2025-12-26	ADPT	16.69	0.33	0.00	2579
2025-12-29	ADPT	16.64	0.32	0.50	2599
2025-12-30	ADPT	16.41	0.32	3.50	2601
2025-12-31	ADPT	16.23	0.37	0.05	2667
2026-01-02	ADPT	15.93	0.37	0.03	2674
2026-01-05	ADPT	16.17	0.37	0.09	2669
2026-01-06	ADPT	16.1	0.38	0.53	2623
2026-01-07	ADPT	16.72	0.42	0.04	2624
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	ADPT	14.86	20.9	-	-0.49
2025-12-10	ADPT	15.76	20.9	-	-0.49
2025-12-11	ADPT	15.43	20.9	-	-0.49
2025-12-12	ADPT	15.44	20.9	-	-0.49
2025-12-15	ADPT	15.69	20.9	-	-0.49
2025-12-16	ADPT	15.69	20.9	-	-0.49
2025-12-17	ADPT	16.12	20.9	-	-0.49
2025-12-18	ADPT	16.50	20.9	-	-0.49
2025-12-19	ADPT	17.00	20.9	-	-0.49
2025-12-22	ADPT	17.45	20.9	-	-0.49
2025-12-23	ADPT	16.72	20.9	-	-0.49
2025-12-26	ADPT	16.69	20.9	-	-0.49
2025-12-29	ADPT	16.65	20.9	-	-0.49
2025-12-30	ADPT	16.42	20.9	-	-0.49
2025-12-31	ADPT	16.23	20.9	-	-0.49
2026-01-02	ADPT	15.90	20.9	-	-0.49
2026-01-05	ADPT	16.17	20.9	-	-0.49
2026-01-06	ADPT	16.10	20.9	-	-0.49
2026-01-07	ADPT	16.73	20.9	-	-0.49
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	ADPT	-15.31	-1.00	7.07
2025-12-10	ADPT	-15.31	-1.00	7.09
2025-12-11	ADPT	-15.31	-1.00	7.09
2025-12-12	ADPT	-15.31	-1.00	7.09
2025-12-15	ADPT	-15.72	-0.99	7.09
2025-12-16	ADPT	-15.72	-0.99	7.09
2025-12-17	ADPT	-15.72	-0.99	7.09
2025-12-18	ADPT	-17.07	-0.99	7.09
2025-12-19	ADPT	-17.07	-0.99	7.09
2025-12-22	ADPT	-17.07	-0.99	7.09
2025-12-23	ADPT	-17.11	-0.99	7.09
2025-12-26	ADPT	-17.11	-0.99	6.64
2025-12-29	ADPT	-17.11	-0.99	6.64
2025-12-30	ADPT	-17.16	-0.99	6.64
2025-12-31	ADPT	-17.16	-0.99	6.64
2026-01-02	ADPT	-17.16	-0.99	6.64
2026-01-05	ADPT	-17.16	-1.01	6.64
2026-01-06	ADPT	-17.16	-1.01	6.64
2026-01-07	ADPT	-17.19	-1.01	6.64
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.15

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.17

Insider Transactions

-17.19

Institutional Transactions

-1.01

Beta

2.18

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

76.5

Max Drawdown 5-Year %

-96.6

Target Price

P/E

Forward P/E

PEG

P/S

10.11

P/B

12.49

P/Free Cash Flow

EPS

-0.54

Average EPS Est. Cur. Y

-0.49

EPS Next Y. (Est.)

-0.57

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-31.5

Relative Volume

0.91

Return on Equity vs Sector %

-66

Return on Equity vs Industry %

-50.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Adaptive Biotechnologies Corpor

Sector: Healthcare

Industry: Biotechnology

Employees: 619

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

stock quote shares ADPT – Adaptive Biotechnologies Corporation Stock Price stock today

news today ADPT – Adaptive Biotechnologies Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch ADPT – Adaptive Biotechnologies Corporation yahoo finance google finance

stock history ADPT – Adaptive Biotechnologies Corporation invest stock market

stock prices ADPT premarket after hours

ticker ADPT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ADPT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y